Scalper1 News
Big-cap biotech Alexion Pharmaceuticals (ALXN) won FDA approval Tuesday for rare-disease drug Kanuma, representing its third-ever drug approval. Kanuma was approved for lysosomal acid lipase deficiency (LAL-D), a genetic condition that brings serious organ damage and premature death. It’s very rare — the more severe form, known as Wolman disease, occurs in only one or two infants per million births, while the milder form, known as cholesteryl Scalper1 News
Scalper1 News